;PMID: 11313934
;source_file_977.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..232] = [t:42..232]
;2)section:[e:236..335] = [t:236..335]
;3)section:[e:339..447] = [t:339..447]
;4)sentence:[e:451..505] = [t:451..505]
;5)sentence:[e:506..762] = [t:506..762]
;6)sentence:[e:764..1016] = [t:764..1016]
;7)sentence:[e:1017..1182] = [t:1017..1182]
;8)sentence:[e:1183..1285] = [t:1183..1285]
;9)sentence:[e:1286..1526] = [t:1286..1526]
;10)sentence:[e:1527..1628] = [t:1527..1628]
;11)sentence:[e:1629..1786] = [t:1629..1786]
;12)sentence:[e:1787..1971] = [t:1787..1971]
;13)sentence:[e:1972..2178] = [t:1972..2178]
;14)section:[e:2182..2227] = [t:2182..2227]

;section 0 Span:0..36
;Oncogene. 2001 Apr 5;20(15):1860-72.
(SEC
  (FRAG (NNP:[0..8] Oncogene) (,:[8..9] .) (CD:[10..14] 2001) (CC:[15..18] Apr)
        ($:[19..24] 5;20-LRB-) (CD:[24..26] 15) (-RRB-:[26..27] -RRB-)
        (CD:[27..32] :1860) (HYPH:[32..33] -) (CD:[33..35] 72) (.:[35..36] .)))

;sentence 1 Span:42..232
;Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 
;Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with
; either sodium butyrate or trichostatin A.
;[100..133]:substance:"1 alpha,25  Dihydroxyvitamin D(3)"
;[142..161]:substance:"19-nor-hexafluoride"
;[162..169]:substance:"analogs"
;[198..213]:substance:"sodium butyrate"
;[217..231]:substance:"trichostatin A"
(SENT
  (NP-HLN
    (NP (JJ:[42..53] Synergistic) (NN:[54..60] growth) (NN:[61..71] inhibition))
    (PP (IN:[72..74] of)
      (NP (NN:[75..83] prostate) (NN:[84..90] cancer) (NNS:[91..96] cells)))
    (PP (IN:[97..99] by)
      (NP
        (NP
          (NP (CD:[100..101] 1) (NN:[102..110] alpha,25)
              (NN:[112..128] Dihydroxyvitamin) (NN:[129..133] D-LRB-3-RRB-))
          (CC:[134..137] and)
          (NP (PRP$:[138..141] its) (NN:[142..161] 19-nor-hexafluoride)
              (NNS:[162..169] analogs)))
        (PP (IN:[170..172] in)
          (NP
            (NP (NN:[173..184] combination))
            (PP (IN:[185..189] with)
              (NP (CC:[191..197] either)
                (NP (NN:[198..204] sodium) (NN:[205..213] butyrate))
                (CC:[214..216] or)
                (NP (NN:[217..229] trichostatin) (NN:[230..231] A))))))))
    (.:[231..232] .)))

;section 2 Span:236..335
;Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, 
;Uskokovic MR, Campbell MJ.
(SEC
  (FRAG (NNP:[236..242] Rashid) (NNP:[243..245] SF) (,:[245..246] ,)
        (NNP:[247..252] Moore) (NNP:[253..255] JS) (NNP:[255..256] ,)
        (NNP:[257..263] Walker) (NNP:[264..265] E) (,:[265..266] ,)
        (NNP:[267..273] Driver) (NNP:[274..276] PM) (,:[276..277] ,)
        (NNP:[278..283] Engel) (NNP:[284..286] J,) (NNP:[287..294] Edwards)
        (NNP:[295..297] CE) (,:[297..298] ,) (NNP:[299..304] Brown)
        (NNP:[305..306] G) (NNP:[306..307] ,) (NNP:[309..318] Uskokovic)
        (NNP:[319..321] MR) (,:[321..322] ,) (NNP:[323..331] Campbell)
        (NNP:[332..335] MJ.)))

;section 3 Span:339..447
;Division of Immunity & Infection, Birmingham University Medical School, 
;Edgbaston, Birmingham, B15 2TH, UK.
(SEC
  (FRAG (NNP:[339..347] Division) (IN:[348..350] of) (NNP:[351..359] Immunity)
        (CC:[360..361] &) (NNP:[362..371] Infection) (,:[371..372] ,)
        (NNP:[373..383] Birmingham) (NNP:[384..394] University)
        (NNP:[395..402] Medical) (NNP:[403..409] School) (,:[409..410] ,)
        (NNP:[412..421] Edgbaston) (,:[421..422] ,) (NNP:[423..433] Birmingham)
        (,:[433..434] ,) (NNP:[435..438] B15) (NNP:[439..442] 2TH)
        (,:[442..443] ,) (NNP:[444..447] UK.)))

;sentence 4 Span:451..505
;Prostate cancer is a major cause of male cancer death.
(SENT
  (S
    (NP-SBJ (NN:[451..459] Prostate) (NN:[460..466] cancer))
    (VP (VBZ:[467..469] is)
      (NP-PRD
        (NP (DT:[470..471] a) (JJ:[472..477] major) (NN:[478..483] cause))
        (PP (IN:[484..486] of)
          (NP (JJ:[487..491] male) (NN:[492..498] cancer) (NN:[499..504] death)))))
    (.:[504..505] .)))

;sentence 5 Span:506..762
;In vitro and in vivo data  support a role for 1 alpha,25 Dihydroxyvitamin
;D(3) (1 alpha,25(OH)(2)D(3)) in  regulating the growth and differentiation of
;the normal prostate gland yet  prostate cancer cells appear significantly
;less sensitive to this action.
;[554..584]:substance:"alpha,25 Dihydroxyvitamin D(3)"
;[586..607]:substance:"1 alpha,25(OH)(2)D(3)"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (ADJP (FW:[506..508] In) (FW:[509..514] vitro))
          (NML-1 (-NONE-:[514..514] *P*)))
        (CC:[515..518] and)
        (NP
          (ADJP (FW:[519..521] in) (FW:[522..526] vivo))
          (NML-1 (NNS:[527..531] data))))
      (VP (VBP:[533..540] support)
        (NP
          (NP (DT:[541..542] a) (NN:[543..547] role))
          (PP (IN:[548..551] for)
            (NP
              (NP (CD:[552..553] 1)
                 (NN:[554..562] alpha,25) (NN:[563..579] Dihydroxyvitamin)
                 (NN:[580..584] D-LRB-3-RRB-))
              (NP (-LRB-:[585..586] -LRB-)
                 (CD:[586..587] 1)
                 (NN:[588..607] alpha,25-LRB-OH-RRB--LRB-2-RRB-D-LRB-3-RRB-)
                (-RRB-:[607..608] -RRB-)))))
        (PP (IN:[609..611] in)
          (S-NOM
            (NP-SBJ (-NONE-:[611..611] *))
            (VP (VBG:[613..623] regulating)
              (NP
                (NP (DT:[624..627] the) (NN:[628..634] growth)
                    (CC:[635..638] and) (NN:[639..654] differentiation))
                (PP (IN:[655..657] of)
                  (NP (DT:[658..661] the) (JJ:[662..668] normal)
                      (NN:[669..677] prostate) (NN:[678..683] gland)))))))))
    (RB:[684..687] yet)
    (S
      (NP-SBJ (NN:[689..697] prostate) (NN:[698..704] cancer)
              (NNS:[705..710] cells))
      (VP (VBP:[711..717] appear)
        (ADJP-PRD
          (ADVP (RB:[718..731] significantly) (RBR:[732..736] less))
          (JJ:[737..746] sensitive)
          (PP (TO:[747..749] to)
            (NP (DT:[750..754] this) (NN:[755..761] action))))))
    (.:[761..762] .)))

;sentence 6 Span:764..1016
;Vitamin D(3) receptor (VDR) content or mutational status do not correlate 
;clearly with the antiproliferative effects of 1 alpha,25(OH)(2)D(3) and 
;therefore it is unclear why prostate cancer cell lines are significantly less
; sensitive to this action.
;[764..785]:substance:"Vitamin D(3) receptor"
;[787..790]:substance:"VDR"
;[885..906]:substance:"1 alpha,25(OH)(2)D(3)"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (NML-2
            (NML
              (NML (NN:[764..771] Vitamin) (NN:[772..776] D-LRB-3-RRB-))
              (NN:[777..785] receptor))
            (NML (-LRB-:[786..787] -LRB-) (NN:[787..790] VDR)
                 (-RRB-:[790..791] -RRB-)))
          (NN:[792..799] content))
        (CC:[800..802] or)
        (NP
          (NML-2 (-NONE-:[802..802] *P*))
          (JJ:[803..813] mutational) (NN:[814..820] status)))
      (VP (VBP:[821..823] do) (RB:[824..827] not)
        (VP (VB:[828..837] correlate)
          (ADVP (RB:[839..846] clearly))
          (PP-CLR (IN:[847..851] with)
            (NP
              (NP (DT:[852..855] the) (JJ:[856..873] antiproliferative)
                  (NNS:[874..881] effects))
              (PP (IN:[882..884] of)
                (NP (CD:[885..886] 1)
                    (NN:[887..906] alpha,25-LRB-OH-RRB--LRB-2-RRB-D-LRB-3-RRB-))))))))
    (CC:[907..910] and)
    (S
      (ADVP (RB:[912..921] therefore))
      (NP-SBJ
        (NP (PRP:[922..924] it))
        (SBAR-3 (-NONE-:[924..924] *EXP*)))
      (VP (VBZ:[925..927] is)
        (ADJP-PRD (JJ:[928..935] unclear))
        (SBAR-3
          (WHADVP-1 (WRB:[936..939] why))
          (S
            (NP-SBJ
              (NML (NN:[940..948] prostate) (NN:[949..955] cancer))
              (NN:[956..960] cell) (NNS:[961..966] lines))
            (VP (VBP:[967..970] are)
              (ADJP-PRD
                (ADVP (RB:[971..984] significantly) (RBR:[985..989] less))
                (JJ:[991..1000] sensitive)
                (PP (TO:[1001..1003] to)
                  (NP (DT:[1004..1008] this) (NN:[1009..1015] action))))
              (ADVP-PRP-1 (-NONE-:[1015..1015] *T*)))))))
    (.:[1015..1016] .)))

;sentence 7 Span:1017..1182
;We hypothesized that the antiproliferative responses  of prostate cancer
;cells to 1 alpha,25(OH)(2)D(3) are suppressed by a process  involving histone
;deacetylation.
;[1099..1120]:substance:"1 alpha,25(OH)(2)D(3)"
;[1160..1167]:substance:"histone"
(SENT
  (S
    (NP-SBJ (PRP:[1017..1019] We))
    (VP (VBD:[1020..1032] hypothesized)
      (SBAR (IN:[1033..1037] that)
        (S
          (NP-SBJ-1
            (NP (DT:[1038..1041] the) (JJ:[1042..1059] antiproliferative)
                (NNS:[1060..1069] responses))
            (PP (IN:[1071..1073] of)
              (NP (NN:[1074..1082] prostate) (NN:[1083..1089] cancer)
                  (NNS:[1090..1095] cells)))
            (PP (TO:[1096..1098] to)
              (NP (CD:[1099..1100] 1)
                  (NN:[1101..1120] alpha,25-LRB-OH-RRB--LRB-2-RRB-D-LRB-3-RRB-))))
          (VP (VBP:[1121..1124] are)
            (VP (VBN:[1125..1135] suppressed)
              (NP-1 (-NONE-:[1135..1135] *))
              (PP (IN:[1136..1138] by)
                (NP-LGS
                  (NP (DT:[1139..1140] a) (NN:[1141..1148] process))
                  (VP (VBG:[1150..1159] involving)
                    (NP (NN:[1160..1167] histone)
                        (NN:[1168..1181] deacetylation))))))))))
    (.:[1181..1182] .)))

;sentence 8 Span:1183..1285
;Sodium butyrate (NaB) and trichostatin A (TSA)  are inhibitors of histone
;deacetylase (HDAC) activity.
;[1183..1198]:substance:"Sodium butyrate"
;[1200..1203]:substance:"NaB"
;[1209..1223]:substance:"trichostatin A"
;[1225..1228]:substance:"TSA"
;[1235..1245]:substance:"inhibitors"
;[1249..1268]:substance:"histone deacetylase"
;[1270..1274]:substance:"HDAC"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1183..1189] Sodium) (NN:[1190..1198] butyrate))
        (NP (-LRB-:[1199..1200] -LRB-) (NN:[1200..1203] NaB)
            (-RRB-:[1203..1204] -RRB-)))
      (CC:[1205..1208] and)
      (NP
        (NP (NN:[1209..1221] trichostatin) (NN:[1222..1223] A))
        (NP (-LRB-:[1224..1225] -LRB-) (NN:[1225..1228] TSA)
            (-RRB-:[1228..1229] -RRB-))))
    (VP (VBP:[1231..1234] are)
      (NP-PRD
        (NP (NNS:[1235..1245] inhibitors))
        (PP (IN:[1246..1248] of)
          (NP
            (NML
              (NML (NN:[1249..1256] histone) (NN:[1257..1268] deacetylase))
              (NML (-LRB-:[1269..1270] -LRB-) (NN:[1270..1274] HDAC)
                   (-RRB-:[1274..1275] -RRB-)))
            (NN:[1276..1284] activity)))))
    (.:[1284..1285] .)))

;sentence 9 Span:1286..1526
;Low doses of NaB or TSA  (300 microM and 15 nM respectively), which alone
;were relatively inactive,  synergized with 1 alpha,25(OH)(2)D(3) in liquid
;and semi-solid agar to inhibit  the growth of LNCaP, PC-3 and DU-145 prostate
;cancer cells.
;[1299..1302]:substance:"NaB"
;[1306..1309]:substance:"TSA"
;[1312..1315]:quantitative-value:"300"
;[1316..1322]:quantitative-units:"microM"
;[1327..1329]:quantitative-value:"15"
;[1330..1332]:quantitative-units:"nM"
;[1403..1424]:substance:"1 alpha,25(OH)(2)D(3)"
;[1450..1454]:substance:"agar"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[1286..1289] Low) (NNS:[1290..1295] doses))
        (PP (IN:[1296..1298] of)
          (NP (NN:[1299..1302] NaB) (CC:[1303..1305] or) (NN:[1306..1309] TSA)))
        (PRN (-LRB-:[1311..1312] -LRB-)
          (NP
            (NP
              (NP (CD:[1312..1315] 300) (NN:[1316..1322] microM))
              (CC:[1323..1326] and)
              (NP (CD:[1327..1329] 15) (NN:[1330..1332] nM)))
            (ADVP (RB:[1333..1345] respectively)))
          (-RRB-:[1345..1346] -RRB-)))
      (,:[1346..1347] ,)
      (SBAR
        (WHNP-3 (WDT:[1348..1353] which))
        (S
          (NP-SBJ-3 (-NONE-:[1353..1353] *T*))
          (ADVP (RB:[1354..1359] alone))
          (VP (VBD:[1360..1364] were)
            (ADJP-PRD (RB:[1365..1375] relatively) (JJ:[1376..1384] inactive))))))
    (,:[1384..1385] ,)
    (VP (VBD:[1387..1397] synergized)
      (PP (IN:[1398..1402] with)
        (NP (CD:[1403..1404] 1)
            (NN:[1405..1424] alpha,25-LRB-OH-RRB--LRB-2-RRB-D-LRB-3-RRB-)))
      (PP-LOC (IN:[1425..1427] in)
        (NP
          (NP (JJ:[1428..1434] liquid)
            (NML-2 (-NONE-:[1434..1434] *P*)))
          (CC:[1435..1438] and)
          (NP
            (ADJP (AFX:[1439..1443] semi) (HYPH:[1443..1444] -)
                  (JJ:[1444..1449] solid))
            (NML-2 (NN:[1450..1454] agar)))))
      (S-ADV
        (NP-SBJ (-NONE-:[1454..1454] *))
        (VP (TO:[1455..1457] to)
          (VP (VB:[1458..1465] inhibit)
            (NP
              (NP (DT:[1467..1470] the) (NN:[1471..1477] growth))
              (PP (IN:[1478..1480] of)
                (NP
                  (NP (NN:[1481..1486] LNCaP)
                    (NML-1 (-NONE-:[1486..1486] *P*)))
                  (,:[1486..1487] ,)
                  (NP (NN:[1488..1492] PC-3)
                    (NML-1 (-NONE-:[1492..1492] *P*)))
                  (CC:[1493..1496] and)
                  (NP (NN:[1497..1503] DU-145)
                    (NML-1 (NN:[1504..1512] prostate) (NN:[1513..1519] cancer)
                           (NNS:[1520..1525] cells))))))))))
    (.:[1525..1526] .)))

;sentence 10 Span:1527..1628
;Still greater  synergy was observed between vitamin D(3) hexafluoride analogs
;and either NaB or  TSA.
;[1571..1596]:substance:"vitamin D(3) hexafluoride"
;[1597..1604]:substance:"analogs"
;[1616..1619]:substance:"NaB"
;[1624..1627]:substance:"TSA"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (RB:[1527..1532] Still) (JJR:[1533..1540] greater))
      (NN:[1542..1549] synergy))
    (VP (VBD:[1550..1553] was)
      (VP (VBN:[1554..1562] observed)
        (NP-1 (-NONE-:[1562..1562] *))
        (PP (IN:[1563..1570] between)
          (NP
            (NP
              
              (NML (NN:[1571..1578] vitamin) (NN:[1579..1583] D-LRB-3-RRB-))
              (NN:[1584..1596] hexafluoride)
              (NNS:[1597..1604] analogs))
            (CC:[1605..1608] and)
            (NP (CC:[1609..1615] either) (NN:[1616..1619] NaB)
                (CC:[1620..1622] or) (NN:[1624..1627] TSA))))))
    (.:[1627..1628] .)))

;sentence 11 Span:1629..1786
;The mechanism appeared to involve neither the cyclin-dependent kinase 
;inhibitor, p21((waf1/cip1)) nor cell cycle arrest, but rather induction of 
;apoptosis.
;[1675..1681]:substance:"cyclin"
;[1692..1698]:substance:"kinase"
;[1700..1709]:substance:"inhibitor"
;[1711..1714]:substance:"p21"
;[1716..1720]:substance:"waf1"
;[1721..1725]:substance:"cip1"
(SENT
  (S
    (NP-SBJ-1 (DT:[1629..1632] The) (NN:[1633..1642] mechanism))
    (VP (VBD:[1643..1651] appeared)
      (S
        (NP-SBJ-1 (-NONE-:[1651..1651] *))
        (VP (TO:[1652..1654] to)
          (VP (VB:[1655..1662] involve)
            (NP
              (NP (CC:[1663..1670] neither)
                (NP
                  (NP (DT:[1671..1674] the)
                    (ADJP (NN:[1675..1681] cyclin) (HYPH:[1681..1682] -)
                          (JJ:[1682..1691] dependent))
                    (NN:[1692..1698] kinase) (NN:[1700..1709] inhibitor))
                  (,:[1709..1710] ,)
                  (NP (NN:[1711..1714] p21)
                    (PRN (-LRB-:[1714..1715] -LRB-)
                      (NP (-LRB-:[1715..1716] -LRB-) (NN:[1716..1720] waf1)
                          (SYM:[1720..1721] /) (NN:[1721..1725] cip1)
                          (-RRB-:[1725..1726] -RRB-))
                      (-RRB-:[1726..1727] -RRB-))))
                (CC:[1728..1731] nor)
                (NP (NN:[1732..1736] cell) (NN:[1737..1742] cycle)
                    (NN:[1743..1749] arrest)))
              (,:[1749..1750] ,)
              (CONJP (CC:[1751..1754] but) (IN:[1755..1761] rather))
              (NP
                (NP (NN:[1762..1771] induction))
                (PP (IN:[1772..1774] of)
                  (NP (NN:[1776..1785] apoptosis)))))))))
    (.:[1785..1786] .)))

;sentence 12 Span:1787..1971
;These data suggest that cells dysregulate the normal pro-apoptotic  signals
;of 1 alpha,25(OH)(2)D(3) during prostate cancer development by a  mechanism
;involving histone deacetylation.
;[1866..1887]:substance:"1 alpha,25(OH)(2)D(3)"
;[1949..1956]:substance:"histone"
(SENT
  (S
    (NP-SBJ (DT:[1787..1792] These) (NNS:[1793..1797] data))
    (VP (VBP:[1798..1805] suggest)
      (SBAR (IN:[1806..1810] that)
        (S
          (NP-SBJ (NNS:[1811..1816] cells))
          (VP (VBP:[1817..1828] dysregulate)
            (NP
              (NP (DT:[1829..1832] the) (JJ:[1833..1839] normal)
                (ADJP (AFX:[1840..1843] pro) (HYPH:[1843..1844] -)
                      (JJ:[1844..1853] apoptotic))
                (NNS:[1855..1862] signals))
              (PP (IN:[1863..1865] of)
                (NP (CD:[1866..1867] 1)
                    (NN:[1868..1887] alpha,25-LRB-OH-RRB--LRB-2-RRB-D-LRB-3-RRB-))))
            (PP (IN:[1888..1894] during)
              (NP (NN:[1895..1903] prostate) (NN:[1904..1910] cancer)
                  (NN:[1911..1922] development)))
            (PP (IN:[1923..1925] by)
              (NP
                (NP (DT:[1926..1927] a) (NN:[1929..1938] mechanism))
                (VP (VBG:[1939..1948] involving)
                  (NP (NN:[1949..1956] histone) (NN:[1957..1970] deacetylation)))))))))
    (.:[1970..1971] .)))

;sentence 13 Span:1972..2178
;Combination therapy with potent  vitamin D(3) analogs and clinically approved
;HDAC inhibitors may overcome this  lesion and improve the treatment of both
;androgen-dependent and independent  prostate cancer.
;[2005..2017]:substance:"vitamin D(3)"
;[2018..2025]:substance:"analogs"
;[2050..2054]:substance:"HDAC"
;[2055..2065]:substance:"inhibitors"
;[2126..2134]:substance:"androgen"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1972..1983] Combination) (NN:[1984..1991] therapy))
      (PP (IN:[1992..1996] with)
        (NP
          (NP (JJ:[1997..2003] potent)
            (NML (NN:[2005..2012] vitamin) (NN:[2013..2017] D-LRB-3-RRB-))
            (NNS:[2018..2025] analogs))
          (CC:[2026..2029] and)
          (NP
            (ADJP (RB:[2030..2040] clinically) (VBN:[2041..2049] approved))
            (NN:[2050..2054] HDAC) (NNS:[2055..2065] inhibitors)))))
    (VP (MD:[2066..2069] may)
      (VP
        (VP (VB:[2070..2078] overcome)
          (NP (DT:[2079..2083] this) (NN:[2085..2091] lesion)))
        (CC:[2092..2095] and)
        (VP (VB:[2096..2103] improve)
          (NP
            (NP (DT:[2104..2107] the) (NN:[2108..2117] treatment))
            (PP (IN:[2118..2120] of)
              (NP (CC:[2121..2125] both)
                (NP
                  (ADJP
                    (NML-1 (NN:[2126..2134] androgen))
                    (HYPH:[2134..2135] -) (JJ:[2135..2144] dependent))
                  (NML-2 (-NONE-:[2144..2144] *P*)))
                (CC:[2145..2148] and)
                (NP
                  (ADJP
                    (NML-1 (-NONE-:[2148..2148] *P*))
                    (JJ:[2149..2160] independent))
                  (NML-2 (NN:[2162..2170] prostate) (NN:[2171..2177] cancer)))))))))
    (.:[2177..2178] .)))

;section 14 Span:2182..2227
;PMID: 11313934 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2182..2186] PMID) (::[2186..2187] :) (CD:[2188..2196] 11313934)
        (IN:[2197..2198] -LSB-) (NNP:[2198..2204] PubMed) (HYPH:[2205..2206] -)
        (JJ:[2207..2214] indexed) (IN:[2215..2218] for)
        (NNP:[2219..2227] MEDLINE-RSB-)))
